MX2018014475A - Methods and compositions for the treatment of secretory disorders. - Google Patents

Methods and compositions for the treatment of secretory disorders.

Info

Publication number
MX2018014475A
MX2018014475A MX2018014475A MX2018014475A MX2018014475A MX 2018014475 A MX2018014475 A MX 2018014475A MX 2018014475 A MX2018014475 A MX 2018014475A MX 2018014475 A MX2018014475 A MX 2018014475A MX 2018014475 A MX2018014475 A MX 2018014475A
Authority
MX
Mexico
Prior art keywords
treatment
methods
disorders
epi
pancreatitis
Prior art date
Application number
MX2018014475A
Other languages
Spanish (es)
Inventor
J Mangelsdorf David
A Kliewer Steven
C Coate Katie
HERNANDEZ Genaro
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2018014475A publication Critical patent/MX2018014475A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the treatment of secretory disorders, and provides novel methods of treatment of these disorders comprising the administration of fibroblast growth factor 21 (FGF21) or derivatives thereof. The methods of the invention are useful in conditions including exocrine pancreatic insufficiency (EPI), for example EPI resulting from cystic fibrosis, alcoholism, pancreatitis, pancreatic cancer, gallstones, celiac disease, high triglycerides, or lupus. The methods of the present invention find further utility in the treatment of salivary flow disorders, for example Sjorgen's syndrome, and the prevention of EPI or pancreatitis resulting from surgical procedures.
MX2018014475A 2016-05-25 2017-05-24 Methods and compositions for the treatment of secretory disorders. MX2018014475A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662341591P 2016-05-25 2016-05-25
PCT/US2017/034288 WO2017205517A1 (en) 2016-05-25 2017-05-24 Methods and compositions for the treatment of secretory disorders

Publications (1)

Publication Number Publication Date
MX2018014475A true MX2018014475A (en) 2019-05-23

Family

ID=60412662

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014475A MX2018014475A (en) 2016-05-25 2017-05-24 Methods and compositions for the treatment of secretory disorders.

Country Status (8)

Country Link
US (2) US11318186B2 (en)
EP (1) EP3463427A4 (en)
JP (1) JP7023518B2 (en)
CN (1) CN109789186A (en)
CA (1) CA3026510A1 (en)
IL (2) IL282455B (en)
MX (1) MX2018014475A (en)
WO (1) WO2017205517A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110997726A (en) 2017-07-06 2020-04-10 耶鲁大学 Compositions and methods for treating or preventing endocrine FGF-associated disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
AU2002322394A1 (en) * 2001-07-30 2003-02-17 Eli Lilly And Company Method for treating diabetes and obesity
CN102802657A (en) 2009-06-11 2012-11-28 诺沃-诺迪斯克有限公司 GLP-1 and FGF21 combinations for treatment of diabetes type 2
TWI644675B (en) 2010-04-09 2018-12-21 可娜公司 Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
EP2580385B1 (en) 2010-06-08 2020-04-29 Arçelik Anonim Sirketi A dryer
JP2013533227A (en) * 2010-06-08 2013-08-22 ノヴォ ノルディスク アー／エス FGF21 analogs and derivatives
US9023791B2 (en) * 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
MY163674A (en) * 2011-07-01 2017-10-13 Ngm Biopharmaceuticals Inc Compositions, uses and method for treatment of metabolic disorders and diseases
TW201315742A (en) * 2011-09-26 2013-04-16 Novartis Ag Dual fuction proteins for treating metabolic disorders
TWI593708B (en) 2011-09-26 2017-08-01 諾華公司 Fusion proteins for treating metabolic disorders
AU2015277438B2 (en) * 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN107108711B (en) * 2014-10-23 2021-11-23 恩格姆生物制药公司 Pharmaceutical compositions comprising peptide variants and methods of use thereof
LT3412302T (en) 2014-10-24 2021-07-26 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof

Also Published As

Publication number Publication date
US11318186B2 (en) 2022-05-03
IL282455A (en) 2021-06-30
CA3026510A1 (en) 2017-11-30
WO2017205517A1 (en) 2017-11-30
EP3463427A1 (en) 2019-04-10
JP2019516764A (en) 2019-06-20
US20190201490A1 (en) 2019-07-04
IL263240A (en) 2018-12-31
IL263240B (en) 2021-05-31
JP7023518B2 (en) 2022-02-22
CN109789186A (en) 2019-05-21
US20220257716A1 (en) 2022-08-18
IL282455B (en) 2022-08-01
EP3463427A4 (en) 2020-03-11

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
MX2021014007A (en) EpCAM BINDING PROTEINS AND METHODS OF USE.
MX2017013562A (en) Microbiome regulators and related uses thereof.
MX2018001532A (en) Anti-angptl8 antibodies and uses thereof.
EP4219713A3 (en) Products and compositions
MX2019000588A (en) Somatostatin modulators and uses thereof.
WO2018175752A8 (en) Optimized antibody compositions for treatment of ocular disorders
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
NZ757081A (en) Somatostatin modulators and uses thereof
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
MX352661B (en) Novel benzopyran kinase modulators.
MX2018012873A (en) Compositions and methods for treatment of diseases associated with trinucleotide repeats in transcription factor four.
MX2019004859A (en) Combination treatments comprising administration of imidazopyrazinones.
MX2013000958A (en) Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma.
MX2023001877A (en) Engineered meganucleases specific for recognition sequences in the pcsk9 gene.
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
MX2019009952A (en) Low-viscosity, high-concentration evolocumab formulations and methods of making the same.
MX2020007586A (en) Process of making somatostatin modulators.
CR20220215A (en) Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
CR20220216A (en) Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
MX2013002118A (en) Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators.
MX2021013602A (en) Jak inhibitors.
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
CR20220656A (en) Multi-specific antibodies binding to bcma
MX2022000712A (en) Nlrp3 modulators.